Dendritic Cell Vaccine for Head and Neck Cancer

Inclusion Criteria: * Squamous cell carcinoma of the head and neck in patients with unresectable recurrent disease or distant metastasis or patients who fail conventional radiation therapy and/or chemotherapy and refuse surgical salvage. * Presence of cervical metastasis that is able to be accessed for injection * Biopsy accessible tumor (metastatic or primary) * \>18 years of age. * The following laboratory values obtained ≤14 days prior to registration: * ANC ≥1500 * PLT ≥100,000 * Hgb ≥ 9.0 g/dL * Alkaline phosphatase ≤3 x UNL * AST ≤3 x UNL * Creatinine ≤1.5 x UNL * Life expectancy ≥6 months. * ECOG performance status 0, 1, or 2. * No chemotherapy for prior 4 weeks. Exclusion Criteria: * Pregnant women. * Nursing women. * Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device {IUD}, abstinence.) * Known HIV infection. * Concurrent use of systemic immunosuppressants. * Other immunocompromising condition that in the opinion of the physician renders the patient a poor candidate for this trial. * Other active cancer requiring therapy to control the disease. * Unwillingness to return for follow-up evaluations over a period of up to 2 years following completion of protocol therapy. * Other intercurrent medical problems that, in the opinion of the investigator, would make participation in the study hazardous for the patient * Patients in whom the otolaryngologist, radiation oncologist, and medical oncologist can not agree on a consensus node to treat. * Patients with CNS metastasis or involvement of sites where an inflammatory response would constitute an immediately life threatening situation.